Phase 1 Norwalk Vaccine Study

• ClinicalTrials.gov Identifier: NCT00806962
• Recruitment Status: Completed
• First Posted: December 11, 2008
• Last Update Posted: May 6, 2015
• Sponsor: LigoCyte Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Takeda ( LigoCyte Pharmaceuticals, Inc. )

Study Description

Brief Summary:

Randomized, double blind, multi-site, study in healthy adults, comparing safety and immunogenicity of two dosage levels of Norwalk VLP Vaccine with adjuvant/excipients and with placebo controls

Primary Objective:

• Safety as determined by occurrence of local intranasal symptoms or other symptoms as reported by a self-administered memory aid for 7 days after each vaccination and hematology, blood chemistry and physical examinations performed by the clinical research staff
• Subjects will also be monitored for Serious Adverse Events (SAEs), and onset of any new medical conditions for 180 days following the last study vaccinations (Day 201).

Secondary Objectives

Evaluations of immunogenicity as determined by:

• Geometric mean titers and seroconversion rate of serum anti- Norwalk VLP IgG and IgA
• Stimulation of anti-Norwalk VLP IgA antibody secreting cells (ASC)
• Presence of antigen specific memory B-cell response

Cells will be collected and stored for possible future evaluation of Norwalk VLP-specific cell-mediated immune (CMI) responses

Study Hypothesis:

The incidence of adverse events after intranasal Norwalk VLP Vaccine will be the same as the incidence of adverse events after intranasal adjuvant/excipients alone. Norwalk VLP Vaccine and adjuvant/excipients will have a higher incidence of mild to moderate nasal adverse events compared to placebo but similar incidence of other adverse events.

Two doses of the 100 µg of Norwalk VLP Vaccine will be more immunogenic than two doses of 50 µg of Norwalk VLP Vaccine. The post-vaccination serum antibody responses, the number of antibody secreting cells (ASC) and IgG and IgA memory B-cell responses directed against Norwalk Virus antigen will be increased after Norwalk VLP Vaccine compared to adjuvant/excipients and to placebo.

Condition or disease	Intervention/treatment	Phase
Norovirus	Drug: Adjuvant/Excipients; Device: placebo; Biological: Norwalk VLP Vaccine	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 61 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: Randomized Double-Blind Placebo-Controlled Phase 1, Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-like Particle Vaccine ( Norwalk VLP Antigen, MPL®, Chitosan, Mannitol, and Sucrose) Compared to Adjuvant/Excipients (MPL®, Chitosan, Mannitol, and Sucrose) and to Placebo (Empty Device
• Study Start Date: November 2008
• Actual Primary Completion Date: October 2009
• Actual Study Completion Date: October 2009

Arms and Interventions

Arm	Intervention/treatment
Experimental: Vaccine Arm 1; 50 µg Norwalk VLP Vaccine + Adjuvant/Excipients	Biological: Norwalk VLP Vaccine; intranasal, 50mcg, 2 doses--21 days apart
Experimental: Vaccine Arm 2; 100 µg Norwalk VLP Vaccine + Adjuvant/Excipients	Biological: Norwalk VLP Vaccine; Intranasal, 100 mcg, 2 doses, 21 days apart
Active Comparator: Adjuvant/Excipients (MPL); 14 mg chitosan, 3 mg mannitol, 3 mg sucrose, and 50 mcg MPL	Drug: Adjuvant/Excipients; intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
Sham Comparator: Empty device; Empty device that contains no dry powder formulation. Actuation of the empty intranasal delivery device will deliver a puff of air per device.	Device: placebo; intranasal, puff of air, 2 doses, 21 days apart

Outcome Measures

Primary Outcome Measures :

1. adverse events [ Time Frame: seven days ]

Secondary Outcome Measures :

1. immunogenicity [ Time Frame: 28 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 50 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Signed written informed consent
2. Age 18 - 50 years, inclusive
3. Good general health as determined by a screening evaluation within 30 days before administration of Norwalk VLP Vaccine, adjuvant/excipients or placebo
4. Expressed interest and availability to fulfill the study requirements
5. Agrees not to become pregnant from the time of study enrollment until at least 56 days after the last administration of Norwalk VLP Vaccine, adjuvant/excipients or placebo; if a woman is sexually active and capable of conception (i.e., no history of hysterectomy or tubal ligation), she must agree to use hormonal or barrier birth control. A woman is eligible if she is monogamous with a male who has had a vasectomy.
6. Demonstrated to be an H type-1 antigen secretor
7. Agrees not to participate in another clinical trial with an investigational product for the entire duration of the study (six months after the last study dose i.e. 201 days)
8. Agrees to storage of unused clinical specimens for an indefinite period of time only for those specimens collected by the University of Maryland CVD for use in future research at the CVD. [A University of Maryland site-specific inclusion criterion]

Exclusion Criteria

1. History of any of the following medical illnesses

   • Chronic rhinitis, runny nose, sneezing
   • Clinically significant nose bleed within the last year
   • Diabetes
   • Cancer
   • Heart disease (hospitalization for a heart attack, arrhythmia, or syncope)
   • Unconsciousness (other than a single brief "concussion")
   • Seizures (other than febrile seizures as a child <5 years old)
   • Recurrent infections (more than 3 hospitalizations for invasive bacterial infections such as pneumonia or meningitis)
   • Asthma requiring treatment with inhaler or medication
   • Any current illness requiring daily medication other than vitamins, birth control, or anti-depressant
2. Blood Type B or AB, regardless of Rh + or -
3. Allergies or hypersensitivity to chitosan, shrimp, other shellfish or any component of the vaccine, adjuvant/excipients or placebo
4. History of nasal surgery of any type (including tonsilectomy/adenoidectomy)

5. Any clinically significant abnormality detected on physical examination, including:

   • Murmur (other than a functional murmur)
   • Focal neurological abnormality
   • Hepatosplenomegaly
   • Lymphadenopathy
   • Jaundice
6. Hypertension (BP > 140/90 mm Hg on two separate days)

7. Any lab abnormality, as listed below:

   • Neutrophils (WBC) outside the normal range
   • Hemoglobin outside the normal range (may be repeated once if outside this limit)
   • Platelet count outside the normal range (may be repeated once if outside this limit)
   • Creatinine outside the normal range (may be repeated once if outside this limit)
   • Glucose > upper limit of normal (may be repeated once if outside this limit)
   • AST or ALT outside the normal range (may be repeated once if outside this limit)
   • Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen
8. For women, positive serum pregnancy test within 7 days and urine pregnancy test within 24 hours of administering either dose of Norwalk VLP Vaccine, adjuvant/excipients or placebo
9. Nursing mother
10. Temperature > 38.0 degrees C (100.4 degrees F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within 3 days of administration of Norwalk VLP Vaccine, adjuvant/excipients or placebo
11. Previous participation in a study of Norovirus vaccines
12. Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months
13. Receipt of an investigational vaccine or drug within 28 days before administration of Norwalk VLP Vaccine, adjuvant/excipients or placebo
14. Other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a subject participating in the trial, would render the subject unable to comply with the protocol or would interfere with the evaluation of the vaccine
15. Failure to pass written examination about this study (70% correct answers required to pass)[A University of Maryland site-specific exclusion criterion]

Contacts and Locations

Locations

United States, Maryland

University of Maryland Center for Vaccine Development

Baltimore, Maryland, United States

United States, Missouri

Saint Louis University

Saint Louis, Missouri, United States, 63104

United States, New York

University of Rochester Medical Center

Rochester, New York, United States, 14642

United States, Ohio

Cincinnati Children's Hospital

Cincinnati, Ohio, United States, 45229

Sponsors and Collaborators

LigoCyte Pharmaceuticals, Inc.

Investigators

• Principal Investigator: John J Treanor, MD; University of Rochester

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, Bargatze RF, Sztein MB, Tacket CO. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis. 2010 Dec 1;202(11):1649-58. doi: 10.1086/657087. Epub 2010 Oct 27. Erratum In: J Infect Dis. 2011 Apr 1;203(7):1036.

• Responsible Party: LigoCyte Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT00806962
• Other Study ID Numbers: LV01-102
• First Posted: December 11, 2008
• Last Update Posted: May 6, 2015
• Last Verified: May 2015

Additional relevant MeSH terms:

Vaccines; Immunologic Factors; Physiological Effects of Drugs